ONCO BRUNO
@brunolarvol
Followers
7K
Following
95K
Media
6K
Statuses
44K
@LARVOL | 100 experts building onco super intelligence | 200,000 KM curves digitized | free for non-commercial use | ex-IBM
San Francisco, CA
Joined March 2014
I’ll be at Patent Pending in NYC tonight around 6:30 PM. If you’re nearby and want to talk oncology data & AI, let’s connect.
0
1
2
Today I re-learned that the first clinical trial was for the treatment of scurvy in 1747 by James Lind—a Scottish naval surgeon who took 12 sailors and divided them into pairs and gave each pair a different remedy! Obviously, the pair that got oranges and lemons did the best!
14
16
106
Restart Smarter Launches During National Hunger & Homelessness Awareness Week: New NJ Non-Profit Bridges Gaps in Housing, Health, and Career Support for Vulnerable Populations
1
1
3
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union https://t.co/TtzQnQSLTP Learn more 👉 https://t.co/cec5qH3CMn
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights
0
5
9
Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation https://t.co/KsdTDR1Z4H Learn more 👉 https://t.co/gQDHNX2sK1
0
4
6
We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by Dr. Aaron Goodman, MD (@Papa_Heme) 👉 https://t.co/rqLENsHfPS AI models more frequently suggested escalation to a
Myeloma question A patient with high risk smoldering myeloma is started on daratumumab. A year later the patient has progressively rising M spike. Otherwise asymptomatic and negative imaging. What do you recommend?
0
4
7
If you are thinking about ditching health insurance all together but are worried about going completely naked in the case something big comes up, you should give CrowdHealth a look. Here is what our CrowdHealth members have paid on average/month over the last 12 months: $143
58
110
903
November is Gastric Cancer Awareness Month. Here's a look at Checkpoint Inhibitors in the Gastric Cancer Treatment Landscape. Adapted from Yang Wang, and Geoffrey Chong: https://t.co/796KfVO7PU
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials
0
11
20
FDA has approved Epkinly (epcoritamab-bysp) for relapsed/refractory follicular lymphoma—both in combination with lenalidomide + rituximab (based on EPCORE FL-1) and as a monotherapy after ≥2 prior systemic therapies. Learn more 👇 EPCORE FL-1: https://t.co/gLFG0dKhi6 EPCORE
0
8
10
Interesting work by @Larvol @brunolarvol with synthetic respondents in Oncology. Seems the synthetic oncologists were far off from the real/human oncologists. The question is though, who is right from a medical POV? #insights #AI #oncology
We asked leading AI models to simulate oncologist poll responses before the actual results were announced and compared their predictions to the original poll by Dr. Aaron Goodman, MD (@Papa_Heme) 👉 https://t.co/rqLENsHfPS AI models more frequently suggested escalation to a
3
3
5
JUST IN: Positive lidERA phase III =>giredestrant (SERD) as adjuvant endocrine therapy in ER+, Her-2 (-) early-stage breast cancer show improvement in iDFS vs. SOC endocrine therapy, via @Roche
https://t.co/wPKqWPwL3w
roche.com
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapyThese unprecedented results support its...
0
4
21
Onco deserves its own Elon. Thanks @DrPatSoonShiong
Thank you Tom. Your support for this work means a lot to the scientists and clinicians working 24/7 to fight cancer
0
1
2
How would you treat a patient with primary hepatic marginal zone lymphoma who is asymptomatic?@tobyeyre82 @CwynKate @graham74GC @AnnaSureda5 @HemSandoval @c_thieblemont @SFBarringtonKCL @GuiperiniMD @ab_pau @Lymphoma_Doc
0
0
2
The Player You Land On Needs To Hit A Game Winning Three Over Victor Wembanyama To Save Your LIfe! Press Pause.... Did You Survive?🤔
2
1
3
Looking forward to it. Who will be there ?
We're headed to Orlando, FL, for @ASH_hematology 2025, December 6-9. If you are attending, let’s connect! Explore more insights and data from #ASH25: https://t.co/5urS4cYnu2
#LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ASH2025 #Hematology #HEMSM
0
4
6
The Cancer Bioshield protecting @ScottAdamsSays NK and T cells while receiving Pluvicto. A universal immunotherapy in action. Ask your doctor what is your ALC?
Scott Adams and a Cancer Teaching Moment. Treating the immune system and protecting the NK and T cells during radiation. The FDA approved mechanism of action of Anktiva. The Bioshield when these precious cancer killing cells are exposed to any radiation.
299
852
7K
Voting in the ASCO Election is open now until December 8! Meet the candidates for the Board of Directors – Designated Radiation Oncologist seat. Learn more about each candidate and make your voice heard at: https://t.co/DQufVdwFw6
0
6
14
HER2+ MBC patient on 2L T-DXd with 14-mo excellent response. Now oligoprogression in a single lung lesion, other sites stable, treatment tolerated well. Next step?"
0
1
5
After playing around with @EvidenceOpen I think it's safe to say writing and publishing medical reviews is over. I asked it to summarize all the JAK inhibitors approved in myelofibrosis and it put it in a nice table for me. It will do this for anything and seems accurate.
13
15
255
Myeloma question A patient with high risk smoldering myeloma is started on daratumumab. A year later the patient has progressively rising M spike. Otherwise asymptomatic and negative imaging. What do you recommend?
0
0
1
Daratumumab is the standard of care for high risk smoldering myeloma, and should be considered as Option 1 (if available) after discussing pros and cons. It’s limited duration therapy that is approved by the FDA and in Europe. Observation alone is fraught with risk even in the
7
9
75